These data suggested that anti-PD1 antibody increased total CD8+ T cells while addition of MS-20 to anti-PD1 antibody further modulated the immunologic tumor microenvironment by increasing activated CD8+ T cells population and downregulating the expression of the immune exhaustion marker PD1. The gene discussed is PDCD1; the disease is neoplasm.